Rasburicase and Tumor Lysis Syndrome: Lower Dosage, Consideration of Indications, and Hyperhydration

被引：17
|
作者：
Darmon, Michael [1 ]
Guichard, Isabelle [1 ]
Vincent, Francois [2 ]
机构：
[1] St Etienne Teaching Hosp, St Etienne, France
[2] Avicenne Teaching Hosp, Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 03期
关键词：
SINGLE-DOSE RASBURICASE; 6; MG; ADULTS; HYPERURICEMIA; PROPHYLAXIS; MANAGEMENT; CANCER;
D O I：
10.1200/JCO.2010.32.6751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [31] Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies
    Wang, LY
    Shih, LY
    Hung, C
    Jou, ST
    Lin, KH
    Yeh, TC
    Lin, SF
    Liang, DC
    ACTA HAEMATOLOGICA, 2006, 115 (1-2) : 35 - 38
  • [32] The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis
    Yu, X.
    Liu, L.
    Nie, X.
    Li, J.
    Zhang, J.
    Zhao, L.
    Wang, X.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (01) : 18 - 26
  • [33] Treatment of impending tumor lysis with single-dose rasburicase
    Lee, ACW
    Li, CH
    So, KT
    Chan, R
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (11) : 1614 - 1617
  • [34] Tumor Lysis Syndrome A Unique Solute Disturbance
    Strauss, Penelope Z.
    Hamlin, Shannan K.
    Dang, Johnny
    NURSING CLINICS OF NORTH AMERICA, 2017, 52 (02) : 309 - +
  • [35] Efficacy of Single Dose Rasburicase (1.5mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome
    Philips, Ashwin
    Radhakrishnan, Venkatraman
    Ganesan, Prasanth
    Ganesan, T. S.
    Ramamurthy, Jaikumar
    Dhanushkodi, Manikandan
    Sagar, T. G.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (04) : 618 - 622
  • [36] Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome
    Patel, Samit
    Le, Ann
    Gascon, Sunshine
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (12) : 1015 - 1016
  • [37] The efficacy and cost-impact of rasburicase 3 mg versus 6 mg for the management of tumor lysis syndrome: A multicenter analysis
    Marjoncu, Dennis
    Holman, Kori
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 893 - 898
  • [38] Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase
    Hummel, Margit
    Reiter, Sebastian
    Adam, Katja
    Hehlmann, Ruediger
    Buchheidt, Dieter
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (04) : 331 - 336
  • [39] A review of tumour lysis syndrome with targeted therapies and the role of rasburicase
    Bose, P.
    Qubaiah, O.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (03) : 299 - 326
  • [40] Tumor lysis syndrome in elderly
    Pumo, Vitalinda
    Sciacca, Dorotea
    Malaguarnera, Mariano
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 (01) : 31 - 42
12345